

## REFERENCES

1. Liang R: HTLV-I associated adult T-cell leukemia/lymphoma in Hong Kong. *Am J Hematol* 45:100, 1994.
2. Seiki M, Hattori S, Hirayama Y, Yoshida M: Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. *Proc Natl Acad Sci USA* 80:3618-3622, 1983.
3. Sherman MP, Saksena NK, Dube DK, Yanagihara R, Poiesz BJ: Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus-type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea. *J Virol* 66:2556-2563, 1992.

### Management of Iron Overload With a Disposable Multi-Day Delivery System

*To the Editor:* Iron overload remains the most serious complication of long-term blood transfusions in patients with thalassaemia major and other transfusion dependent anemias. Regular desferrioxamine administration has been shown to prevent iron-related cardiac disease [1] and to extend survival in transfused patients [2]. In many patients, compliance to subcutaneous desferrioxamine therapy is poor because preparation of the solution is demanding and the nightly administration by syringe pump is irritating. Therefore, the prevention of iron-related morbidity remains a serious problem for many patients. Some centres have reported success with intensive intravenous iron chelation for patients with severe iron overload with, or at risk of, cardiac disease [3,4]. Because the ambulatory long-term intravenous therapy can provoke quality of life modifications for discontinuous scholastic and/or working activity, we provided domiciliary nursing assistance for the patients involved in our study.

Five thalassaemic patients, aged 12-15, were treated between June and December 1994 with a desferrioxamine dose of 40-60 mg/Kg/24 hr for 5 consecutive days, weekly for 26 consecutive weeks. The drug solution was prepared in hospital in a multi-day elastomeric disposable pump, the LV2 Infusor (Baxter, Deerfield, IL), with a reservoir volume of 250 ml. The Infusor was connected to a Port-a-Cath (SIMS-Deltec, Minneapolis, MN) placed on the anterior chest wall. The compliance with this protocol was considerably better than with the conventional treatment protocol. Patients commented favourably on the lightness and size of the device as well as its silence and simple operation. In addition, by eliminating the patient's responsibility for preparing their desferrioxamine solution, and by providing a domiciliary nursing service to assist with the administration, compliance was significantly improved with a corresponding reduction in ferritin levels. Before treatment, serum ferritin ranged from 3,000 to 5,100 mcg/l (mean  $3840 \pm 850$  SD). Following 26 weeks of therapy, values ranged from 450 to 1,000 mcg/l (mean  $668 \pm 228$  SD), a mean decrease of 82.8% (range 80-85%).

Drs. Fielding and Wonke [5] have used a disposable single-day elastomeric pump for intravenous desferrioxamine infusion. In contrast, we have introduced a multi-day elastomeric pump with the addition of domiciliary nursing assistance to reduce the risk of infection from faulty aseptic techniques in young children. Using the domiciliary support, no infectious complications were reported. All patients have expressed satisfaction with the domiciliary protocol because their scholastic activities were not affected and their quality of life was improved. The economics of this method of treatment were compared to the conventional pump, with net savings observed in favour of the elastomeric pump.

In summary, we conclude that the disposable multi-day pump is eminently suitable for long-term intravenous chelation therapy in young, iron-overloaded thalassaemic patients.

CIANCILLI PAOLO  
SORRENTINO FRANCESCO  
AMADORI SERGIO

Department of Hematology, St. Eugenio Hospital, University  
"Tor Vergata," Rome, Italy

## REFERENCES

1. Wolfe C, Olivieri NF, Sallan D, Colan S, Rose V, Propper R, Freeman MH, Nathan DG: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. *N Engl J Med* 312:1600-1603, 1985.
2. Zurlo MG, De Stefano PD, Borgna-Pignatti C, DiPalma A, Piga A, Melendi C, DiGregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassemia major. *Lancet* ii:27-30, 1989.
3. Choen AR, Mizanin J, Schwartz E: Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. *J Pediatr* 115:151-155, 1989.
4. Cianiulli P, Forte L, Sorrentino F, Palombi M, Papa G, Mariani MG: Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients. *Bone Marrow Transplant* 12 (Suppl 1):5-8, 1993.
5. Fielding A, Wonke B: Novel delivery system for continuous desferrioxamine infusion in iron-overloaded patients. *Lancet* 340:790-791, 1992.

### Concurrent Epiphyseal Fracture and Leukemia in a Patient Treated With Growth Hormone

*To the Editor:* Pituitary growth hormone (GH) has been used as a therapeutic agent for the GH-deficient child for more than 30 years. The recent availability of biosynthetic GH has favored its use in a number of so-called "nonconventional" indications, with the expectation that all cases will be treated effectively and safely.

However, the literature raises growing concern about untoward adverse effects and oncogenic potential of GH. Until now, leukemia has been observed in at least 33 patients who had received both pituitary and recombinant GH in moderate doses [1,2]. There was a mean time of 5 years between start of GH therapy and onset of leukemia. Despite the number of case-reports, definite epidemiological evidence of a relationship between GH treatment in pediatric patients and leukemia or other malignancies is still lacking.

Nevertheless, there is some in vitro evidence in both animal models and humans suggesting a role of GH in hemopoietic disorders. GH enhances the proliferation of human leukemic blasts freshly obtained from acute leukemia (both lymphoid and myeloid types) [3]. GH also enhances granulocytic colony growth through a pathway involving insulin-like growth factor/somatomedin C [4].

We recently observed acute lymphoblastic leukemia in an 18-year-old white male, treated with recombinant GH for pituitary dwarfism. GH therapy was started at age 14 years and was continued for 34 months, resulting in growth acceleration. Fourteen months after GH discontinuation, the patient suffered from an epiphyseal fracture of the right tibia. The fracture was apparently related to a modest trauma. Six months later he developed a recurrent epiphyseal fracture of the right tibia, and he was admitted to hospital for orthopedic surgery. Hemogram at admission showed marked leukocytosis and presence of blast cells. Diagnosis of acute lymphoblastic leukemia pre-B phenotype FAB L2 was made, and the patient underwent induction chemotherapy.

Our case increases the number of reported malignancies following GH use. No additional leukemia risk factor could be assessed. The latency period between GH treatment and leukemia onset falls within limits observed in the literature. Clinical features at onset of leukemia in this case are impressive; in fact, pathological fractures are also extremely rare in pediatric leukemia patients (7% or less) and generally involve the spine [5]. It is interesting to note that osteoclasts may derive from pluripotent hemopoietic